Partnership will enhance patient adherence and engagement programs through targeted and personalized recommendations that will empower at-risk patients to ultimately make healthier choices.
Studies have shown that medication nonadherence can be caused by a mix of situational and behavioral barriers that are unique to each patient and their health journey. With the use of AllazoHealth’s proprietary AllazoEngine, which precisely identifies at-risk patients through predictive analytics, Lash Group will be the first HUB services provider to leverage individualized patient predicted risk along with machine learning to provide personalized interventions that are unique to behaviors and treatment plans.
“At Lash Group, we are committed to providing the right blend of high-technology and high-touch services that drive patient engagement and ultimately improve the patient healthcare journey. By coupling an innovative technology solution, like the AllazoEngine, with Lash Group’s existing team of accredited, high-quality counselors and clinicians, we can offer our partners an advanced solution that will reduce barriers to treatment, increase access and enhance health outcomes,” said Tommy Bramley, President of Lash Group.
As part of its patient adherence and engagement offerings, Lash Group will leverage the AllazoEngine to recommend a specific cadence and intervention type through methods such as motivational text messages to patients, targeted touchpoints made by a clinician, or simple reminders delivered through our multi-channel services. The ability to correlate specific patient behavior with predictive risk allows Lash Group to adjust its communication style with each patient and recommend the most appropriate interventions within the care map.
The AllazoEngine is the only AI platform with effectiveness validated through peer-reviewed Randomized Control Trial (RCT). In fact, according to the RCT, the AllazoEngine was proven to achieve a 5.5x greater adherence uplift compared to traditional programs.
“We are pleased to be joining forces with Lash Group to provide better, more personalized support for patients of all types, and are excited by the opportunity to support Lash Group’s patients as part of their adherence programs,” said Clifford Jones, CEO of AllazoHealth.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500, with more than $160 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com.
About AllazoHealth
AllazoHealth is a machine learning company that focuses on driving the behavioral change of patients through personalized and proactive intervention. Our mission is to be the leader in precision engagement & predictive analytics, revolutionizing the way our enterprise healthcare clients engage and improve the health of their patient population. For more information about AllazoHealth - https://allazohealth.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005555/en/
Source: AmerisourceBergen
View this news release online at:
http://www.businesswire.com/news/home/20190304005555/en
